Success Metrics

Clinical Success Rate
100.0%

Based on 14 completed trials

Completion Rate
100%(14/14)
Active Trials
1(6%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
5
31%
Ph phase_4
5
31%
Ph phase_1
4
25%
Ph phase_2
2
13%

Phase Distribution

4

Early Stage

2

Mid Stage

10

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
4(25.0%)
Phase 2Efficacy & side effects
2(12.5%)
Phase 3Large-scale testing
5(31.3%)
Phase 4Post-market surveillance
5(31.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

14 of 14 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

16

all time

Status Distribution
Active(1)
Completed(14)
Other(1)

Detailed Status

Completed14
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (25.0%)
Phase 22 (12.5%)
Phase 35 (31.3%)
Phase 45 (31.3%)

Trials by Status

recruiting16%
completed1488%
unknown16%

Recent Activity

Clinical Trials (16)

Showing 16 of 16 trials
NCT06284876Phase 3

Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer

Recruiting
NCT05237297Phase 1

Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Naproxen, Aceclofenac, Celecoxib and Ilaprazole

Completed
NCT05558150Phase 1

Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Ilaprazole and Aceclofenac

Completed
NCT03444883Phase 3

Phase III Study to Evaluate Safety and Efficacy of Ilaprazole in Patients With NERD

Completed
NCT02638584Phase 4

Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD.

Completed
NCT02666976Phase 4

The Prospective Study on the Effect of Ilaprazole in Non-erosive Reflux Disease Patients; Focused on Histologic Findings and Inflammatory Biomarker

Completed
NCT02648659Phase 4

The Pilot Study on Tailored Eradication Therapy According to Clarithromycin Resistance in H.Pylori Patients

Completed
NCT03362281Phase 3

Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients

Completed
NCT03362268Phase 2

IIaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients

Completed
NCT03139253Phase 4

Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment

Unknown
NCT02873065Phase 4

Efficacy and Safety of 1-week Triple Therapy With Ilaprazole for the Eradication of Helicobacter Pylori

Completed
NCT02084420Phase 3

Efficacy/Safety Study as H. Pylori Eradication of Triple Therapy for 7 Days Treatment

Completed
NCT01820143Phase 1

Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety

Completed
NCT01688544Phase 1

Pharmacokinetic/Pharmacodynamic Study of Ilaprazole to Evaluate the Effect of CYP Genetic Polymorphism

Completed
NCT00471094Phase 2

Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis

Completed
NCT01509261Phase 3

Efficacy Study of Ilaprazole to Treat Erosive Esophgitis

Completed

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16